Table 1 |
|
Arguments implying a role for alterations in TGFβ signaling in osteoarthritis development |
|
Genetic studies point to a role for TGFβ in osteoarthritis |
|
Mice that express a dominant negative TGFβ type II receptor in skeletal tissues showed enhanced chondrocyte hypertrophy and osteoarthritis |
|
Mice deficient for Smad3 or latent TGFβ binding protein 3 demonstrated enhanced chondrocyte hypertrophy and osteoarthritis |
|
Cartilage protective effects of TGFβ are lost in ageing mice |
|
ALK1/ALK5 expression ratio is increased in cartilage in ageing mice and experimental osteoarthritis |
|
ALK1 overexpression results in MMP-13 upregulation in chondrocytes |
|
Blocking ALK5 expression, using siRNA, leads to elevated expression of MMP-13 |
|
In human osteoarthritis cartilage, ALK1 expression and MMP-13 expression significantly correlate |
|
Smad2/3 signaling inhibits, while Smad1/5/8 signaling stimulates, progression of chondrocyte differentiation |
|
In osteoarthritis, synthesis of matrix molecules (type II collagen) is increased - indicating no dominant role for catabolic cytokines |
|
Alterations in TGFβ signaling in osteoarthritis can provide an explanation for the enigmatic observation of concomitant increased synthesis of matrix molecules (type II collagen) and increased MMP-13 production |
|
|
|
MMP-13, matrix metalloproteinase 13; TGFβ, transforming growth factor beta. |
|
van der Kraan et al. Arthritis Research & Therapy 2010 12:201 doi:10.1186/ar2896 |